[1] GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J]. Lacent, 2015, 385:117-171.
[2] Castro HH, Alencar AP, Bense ñ or IM, Lotufo PA, Goulart AC. Multimorbidities are associated to lower survival in ischaemic stroke:results from a Brazilian Stroke Cohort (EMMA Study)[J]. Cerebrovasc Dis, 2017, 44:232-239.
[3] Carrilho Romeiro A, Valadas A, Marques J. Acute ischemic stroke on cancer patients, a distinct etiology:a case-control study[J]? Acta Med Port, 2015, 28:613-618.
[4] Kim JM, Jung KH, Park KH, Lee ST, Chu K, Roh JK. Clinical manifestation of cancer related stroke:retrospective case-control study[J]. J Neurooncol, 2013, 111:295-301.
[5] Kim SJ, Park JH, Lee MJ, Park YG, Ahn MJ, Bang OY. Clues to occult cancer in patients with ischemic stroke[J]. PLoS One, 2012, 7:e44959.
[6] Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer[J]. Medicine (Baltimore), 1985, 64:16-35.
[7] Selvik HA, Bjerkreim AT, Thomassen L, Waje-Andreassen U, Naess H, Kvistad CE. When to screen ischaemic stroke patients for cancer[J]. Cerebrovasc Dis, 2018, 45:42-47.
[8] Grazioli S, Paciaroni M, Agnelli G, Acciarresi M, Alberti A, D'Amore C, Caso V, Venti M, Guasti L, Ageno W, Squizzato A. Cancer-associated ischemic stroke:a retrospective multicenter cohort study[J]. Thromb Res, 2018, 165:33-37.
[9] Selvik HA, Thomassen L, Bjerkreim AT, Næss H. Cancer-associated stroke:the Bergen NORSTROKE study[J]. Cerebrovasc Dis Extra, 2015, 5:107-113.
[10] Zhang YY, Cordato D, Shen Q, Sheng AZ, Hung WT, Chan DK. Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer:a nested case-control study[J]. Cerebrovasc Dis, 2007, 23:181-187.
[11] Oberndorfer S, Nussgruber V, Berger O, Lahrmann H, Grisold W. Stroke in cancer patients:a risk factor analysis[J]. J Neurooncol, 2009, 94:227.
[12] Jiang JW, Gao J, Wang JR, Shang XL. Clinical study of cancer-associated ischemic stroke[J]. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi, 2019, 19:354-360.[姜季委, 高洁, 王继蕊, 商秀丽. 癌症相关缺血性卒中的临床研究[J]. 中国现代神经疾病杂志, 2019, 19:354-360.]
[13] Zhou M, Wang H, Zeng X, Yin P, Zhu J, Chen W, Li X, Wang L, Wang L, Liu Y, Liu J, Zhang M, Qi J, Yu S, Afshin A, Gakidou E, Glenn S, Krish VS, Miller-Petrie MK, Mountjoy-Venning WC, Mullany EC, Redford SB, Liu H, Naghavi M, Hay SI, Wang L, Murray CJL, Liang X. Mortality, morbidity, and risk factors in China and its provinces, 1990-2017:a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394:1145-1158.
[14] Sanossian N, Djabiras C, Mack WJ, Ovbiagele B. Trends in cancer diagnoses among inpatients hospitalized with stroke[J]. J Stroke Cerebrovasc Dis, 2013, 22:1146-1150.
[15] Quintas S, Rogado J, Gullón P, Pacheco-Barcia V, Dotor García-Soto J, Reig-Roselló G, Mondéjar R, Colomer R, Vivancos J. Predictors of unknown cancer in patients with ischemic stroke[J]. J Neurooncol, 2018, 137:551-557.
[16] Zis P, Assi A, Kravaritis D, Sevastianos VA. Ischemic stroke as the first manifestation of hepatic epithelioid hemangioendothelioma[J]. J Stroke Cerebrovasc Dis, 2014, 23:E237-240.
[17] Navi BB, Reiner AS, Kamel H, Iadecola C, Okin PM, Elkind MS, Panageas KS, DeAngelis LM. Risk of arterial thromboembolism in patients with cancer[J]. J Am Coll Cardiol, 2017, 70:926-938.
[18] Schwarzbach CJ, Schaefer A, Ebert A, Held V, Bolognese M, Kablau M, Hennerici MG, Fatar M. Stroke and cancer:the importance of cancer associated hypercoagulation as a possible stroke etiology[J]. Stroke, 2012, 43:3029-3034.
[19] Navi BB, Reiner AS, Kamel H, Iadecola C, Elkind MS, Panageas KS, DeAngelis LM. Association between incident cancer and subsequent stroke[J]. Ann Neurol, 2015, 77:291-300.
[20] Navi BB, Singer S, Merkler AE, Cheng NT, Stone JB, Kamel H, Iadecola C, Elkind MS, DeAngelis LM. Recurrent thromboembolic events after ischemic stroke in patients with cancer[J]. Neurology, 2014, 83:26-33.
[21] Karli ńska AG, Gromadzka G, Karliński MA, Cz?onkowska A. The activity of malignancy may determine stroke pattern in cancer patients[J]. J Stroke Cerebrovasc Dis, 2015, 24:778-783.
[22] Kneihsl M, Enzinger C, Wünsch G, Khalil M, Culea V, Urbanic-Purkart T, Payer F, Niederkorn K, Fazekas F, Gattringer T. Poor short-term outcome in patients with ischaemic stroke and active cancer[J]. J Neurol, 2016, 263:150-156.
[23] Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, Colwell CW. Prevention of venousthromboembolism:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition)[J]. Chest, 2008, 133:S381-453.
[24] Zhang YY, Chan DK, Cordato D, Shen Q, Sheng AZ. Stroke risk factor, pattern and outcome in patients with cancer[J]. Acta Neurol Scand, 2006, 114:378-383.
[25] Gon Y, Okazaki S, Terasaki Y, Sasaki T, Yoshimine T, Sakaguchi M, Mochizuki H. Characteristics of cryptogenic stroke in cancer patients[J]. Ann Clin Transl Neurol, 2016, 3:280-287.
[26] Schulz UG. Cryptogenic stroke-how to make sense of a non-diagnostic entity[J]. Maturitas, 2019, 122:44-50.
[27] Finelli PF, Nouh A. Three-territory DWI acute infarcts:diagnostic value in cancer-associated hypercoagulation stroke (Trousseau syndrome)[J]. AJNR Am J Neuroradiol, 2016, 37:2033-2036.
[28] Gon Y, Sakaguchi M, Takasugi J, Kawano T, Kanki H, Watanabe A, Oyama N, Terasaki Y, Sasaki T, Mochizuki H. Plasma D-dimer levels and ischaemic lesions in multiple vascular regions can predict occultcancer in patients with cryptogenic stroke[J]. Eur J Neurol, 2017, 24:503-508.
[29] Sun B, Fan S, Li Z, Guo W, Liu L, Zhou Y, Ji L, Zhang L, Huang X. Clinical and neuroimaging features of acute ischemic stroke in cancer patients[J]. Eur Neurol, 2016, 75:292-299.
[30] Aarnio K, Joensuu H, Haapaniemi E, Melkas S, Kaste M, Tatlisumak T, Putaala J. Cancer in young adults with ischemic stroke[J]. Stroke, 2015, 46:1601-1606.
[31] Varki A. Trousseau's syndrome:multiple defnitions and multiple mechanisms[J]. Blood, 2007, 110:1723-1729.
[32] Neilson LE, Rogers LR, Sundararajan S. Evaluation and treatment of a patient with recurrent stroke in the setting of active malignancy[J]. Stroke, 2018, 18:STROKEAHA118022088.
[33] Dearborn JL, Urrutia VC, Zeiler SR. Stroke and cancer:a complicated relationship[J]. J Neurol Transl Neurosci, 2014, 2:1039.
[34] Kazmierczak M, Lewandowski K, Wojtukiewicz MZ, Turowiecka Z, Ko?acz E, Lojko A, Skrzydlewska E, Zawilska K, Komarnicki M. Cancer procoagulant in patients with adenocarcinomas[J]. Blood Coagul Fibrinolysis, 2005, 16:543-547.
[35] Bang OY, Chung JW, Lee MJ, Kim SJ, Cho YH, Kim GM, Chung CS, Lee KH, Ahn MJ, Moon GJ. Cancer cell-derived extracellular vesicles are associated with coagulopathy causing ischemic stroke via tissue factor-independent way:the OASIS-CANCER study[J]. PLoS One, 2016, 11:E0159170.
[36] Yeh ET, Chang HM. Cancer and clot:between a rock and a hard place[J]. J Am Coll Cardiol, 2017, 70:939-941.
[37] Liu J, Frishman WH. Nonbacterial thrombotic endocarditis:pathogenesis, diagnosis, and management[J]. Cardiol Rev, 2016, 24:244-247.
[38] Seok JM, Kim SG, Kim JW, Chung CS, Kim GM, Lee KH, Bang OY. Coagulopathy and embolic signal in cancer patients with ischemic stroke[J]. Ann Neurol, 2010, 68:213-219.
[39] Saynak M, Cosar-Alas R, Yurut-Caloglu V, Caloglu M, Kocak Z, Uzal C. Chemotherapy and cerebrovascular disease[J]. J Buon, 2008, 13:31-36.
[40] Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, Liu JS, Huang CH. Incidence of ischemic stroke post-chemotherapy:a retrospective review of 10, 963 patients[J]. Clin Neurol Neurosurg, 2006, 108:150-156.
[41] Lysov Z, Dwivedi DJ, Gould TJ, Liaw PC. Procoagulant effects of lung cancer chemotherapy:impact on microparticles and cell-free DNA[J]. Blood Coagul Fibrinolysis, 2017, 28:72-82.
[42] Rogers LR. Cerebrovascular complications in cancer patients[J]. Neurol Clin, 2003, 21:167-192.
[43] Murthy SB, Karanth S, Shah S, Shastri A, Rao CP, Bershad EM, Suarez JI. Thrombolysis for acute ischemic stroke in patients with cancer:a population study[J]. Stroke, 2013, 44:3573-3576.
[44] Yang TL, Wu TC, Huang CC, Huang PH, Chung CM, Lin SJ, Chen JW, Chan WL, Chiang CH, Leu HB. Association of tamoxifen use and reduced cardiovascular events among Asian females with breast cancer[J]. Circ J, 2014, 78:135-140.
[45] Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke:a nationwide Danish population-based cohort study[J]. Eur Urol, 2014, 65:704-709.
[46] Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, Zhao D, Niu Y. Stroke related to androgen deprivation therapy for prostate cancer:a meta-analysis and systematic review[J]. BMC Cancer, 2016, 16:180.
[47] Adams HP Jr. Cancer and cerebrovascular disease[J]. Curr Neurol Neurosci Rep, 2019, 19:73.
[48] Stewart FA, Hoving S, Russell NS. Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients[J]. Radiat Res, 2010, 174:865-869.
[49] Passos J, Nzwalo H, Marques J, Azevedo A, Netto E, Nunes S, Salgado D. Late cerebrovascular complications after radiotherapy for childhood primary central nervous system tumors[J]. Pediatr Neurol, 2015, 53:211-215.
[50] Cheng SW, Ting AC, Ho P, Wu LL. Accelerated progression of carotid stenosis in patients with previous external neck irradiation[J]. J Vasc Surg, 2004, 39:409-415.
[51] El-Fayech C, Haddy N, Allodji RS, Veres C, Diop F, Kahlouche A, Llanas D, Jackson A, Rubino C, Guibout C, Pacquement H, Oberlin O, Thomas-Teinturier C, Scarabin PY, Chavaudra J, Lefkopoulos D, Giroud M, Bejot Y, Bernier V, Carrie C, Diallo I, de Vathaire F. Cerebrovascular diseases in childhood cancer survivors:role of the radiation dose to Willis circle arteries[J]. Int J Radiat Oncol Biol Phys, 2017, 97:278-286.
[52] Katz JM, Segal AZ. Incidence and etiology of cerebrovascular disease in patients with malignancy[J]. Curr Atheroscler Rep, 2005, 7:280-288.
[53] Silvis SM, Hiltunen S, Lindgren E, Jood K, Zuurbier SM, Middeldorp S, Putaala J, Cannegieter SC, Tatlisumak T, Coutinho JM. Cancer and risk of cerebral venous thrombosis:a case-control study[J]. J Thromb Haemost, 2018, 16:90-95.
[54] Klein P, Haley EC, Wooten GF, Vanden Berg SR. Focal cerebral infarctions associated with perivascular tumor infltrates in carcinomatous leptomeningeal metastases[J]. Arch Neurol, 1989, 46:1149-1152.
[55] Ohshima K, Tsujii Y, Sakai K, Oku H, Morii E. Massive tumor embolism in the abdominal aorta from pulmonary squamous cell carcinoma:case report and review of the literature[J]. Pathol Int, 2017, 67:467-471.
[56] Zheng Z, Guo G, Xu L, Lei L, Wei X, Pan Y. Left atrial myxoma with versus without cerebral embolism:length of symptoms, morphologic characteristics, and outcomes[J]. Tex Heart Inst J, 2014, 41:592-595.
[57] Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke:a guideline for healthcare professionals from the American Heart Association/American Stroke Association[J]. Stroke, 2018, 49:E46-110.
[58] Cappellari M, Carletti M, Micheletti N, Tomelleri G, Ajena D, Moretto G, Bovi P. Intravenous alteplase for acute ischemic stroke in patients with current malignant neoplasm[J]. J Neurol Sci, 2013, 325:100-102.
[59] Murthy SB, Karanth S, Shah S, Shastri A, Rao CP, Bershad EM, Suarez JI. Thrombolysis for acute ischemic stroke in patients with cancer:a population study[J]. Stroke, 2013, 44:3573-3576.
[60] Sobolewski P, Brola W, Szczuchniak W, Fudala M, Sobota A. Safety of intravenous thrombolysis for acute ischaemic stroke including concomitant neoplastic disease sufferers-experience from Poland[J]. Int J Clin Pract, 2015, 69:666-673.
[61] Merkler AE, Marcus JR, Gupta A, Kishore SA, Leifer D, Patsalides A, DeAngelis LM, Navi BB. Endovascular therapy for acute stroke in patients with cancer[J]. Neurohospitalist, 2014, 4:133-135.
[62] Cho BH, Yoon W, Kim JT, Choi KH, Kang KW, Lee JH, Cho KH, Park MS. Outcomes of endovascular treatment in acute ischemic stroke patients with current malignancy[J]. Neurol Sci, 2019, 41:379-385.
[63] Jung S, Jung C, Hyoung Kim J, Se Choi B, Jung Bae Y, Sunwoo L, Geol Woo H, Young Chang J, Joon Kim B, Han MK, Bae HJ. Procedural and clinical outcomes of endovascular recanalization therapy in patients with cancer-related stroke[J]. Interv Neuroradiol, 2018, 24:520-528.
[64] Lee MJ, Chung JW, Ahn MJ, Kim S, Seok JM, Jang HM, Kim GM, Chung CS, Lee KH, Bang OY. Hypercoagulability and mortality of patients with stroke and active cancer:the OASIS-CANCER study[J]. J Stroke, 2017, 19:77-87.
[65] Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, Brenner B, Kakkar A, Rafii H, Solymoss S, Brilhante D, Monreal M, Bounameaux H, Pabinger I, Douketis J; International Initiative on Thrombosis and Cancer (ITAC) Advisory Panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. Lancet Oncol, 2019, 20:E566-581.
[66] Rojas-Hernandez CM, Oo TH. Direct oral anticoagulants in the prevention and treatment of venous thromboembolism in patients with cancer:new insights from randomized controlled trials[J]. Drugs, 2019, 79:621-631.
[67] Nam KW, Kim CK, Kim TJ, An SJ, Oh K, Ko SB, Yoon BW. Treatment of cryptogenic stroke with active cancer with a new oral anticoagulant[J]. J Stroke Cerebrovasc Dis, 2017, 26:2976-2980.
[68] Gon Y, Sakaguchi M, Takasugi J, Mochizuki H. Ischemic stroke in cancer patients treated with direct oral anticoagulants for venous thromboembolism[J]. Thromb Res, 2017, 154:16-18.
[69] Naito H, Nezu T, Hosomi N, Aoki S, Ueno H, Ochi K, Maruyama H. Antithrombotic therapy strategy for cancer-associated ischemic stroke:a case series of 26 patients[J]. J Stroke Cerebrovasc Dis, 2018, 27:E206-211.
[70] Franco-Moreno A, Cabezón-Gutiérrez L, Palka-Kotlowsa M, Villamayor-Delgado M, García-Navarro M. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis:an update[J]. J Thromb Thrombolysis, 2019, 47:409-419.
[71] Kamphuisen PW, Beyer-Westendorf J. Bleeding complications during anticoagulant treatment in patients with cancer[J]. Thromb Res, 2014, 133:S49-55.
[72] Li N. Platelets in cancer metastasis:to help the "villain" to do evil[J]. Int J Cancer, 2016, 138:2078-2087.
[73] Navi BB, Marshall RS, Bobrow D, Singer S, Stone JB, DeSancho MT, DeAngelis LM. Enoxaparin vs aspirin in patients with cancer and ischemic stroke:the TEACH pilot randomized clinical trial[J]. JAMA Neurol, 2018, 75:379-381.
[74] Saposnik G, Kapral MK, Liu Y, Hall R, O'Donnell M, Raptis S, Tu JV, Mamdani M, Austin PC; Investigators of the Registry of the Canadian Stroke Network, Stroke Outcomes Research Canada (SORCan) Working Group. Iscore:a risk score to predict death early after hospitalization for an acute ischemic stroke[J]. Circulation, 2011, 123:739-749.
[75] Cutting S, Wettengel M, Conners JJ, Ouyang B, Busl K. Three-month outcomes are poor in stroke patients with cancer despite acute stroke treatment[J]. J Stroke Cerebrovasc Dis, 2017, 26:809-815.
[76] Kassubek R, Bullinger L, Kassubek J, Dreyhaupt J, Ludolph AC, Althaus K, Lewerenz J. Identifying ischemic stroke associated with cancer:a multiple model derived from a case-control analysis[J]. J Neurol, 2017, 264:781-791.
[77] Nam KW, Kim CK, Kim TJ, An SJ, Demchuk AM, Kim Y, Jung S, Han MK, Ko SB, Yoon BW. D-dimer as a predictor of early neurologic deterioration in cryptogenic stroke with active cancer[J]. Eur J Neurol, 2017, 24:205-211.
[78] Navi BB, Kamel H, Sidney S, Klingman JG, Nguyen-Huynh MN, Johnston SC. Validation of the stroke prognostic instrument-Ⅱ in a large, modern, community-based cohort of ischemic stroke survivors[J]. Stroke, 2011, 42:3392-3396.